Safety board raises concern over AstraZeneca COVID-19 vaccine efficacy

By The Science Advisory Board staff writers

March 23, 2021 -- Late in the day on March 22, the data safety monitoring board (DSMB) notified the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, and AstraZeneca that it was concerned about information released by AstraZeneca that may result in an incomplete view of efficacy data. In response, AstraZeneca released a statement expressing the company's intention to work with the DSMB and release results of the primary analysis within 48 hours.

According to the DSMB, the information released by AstraZeneca in its interim analysis of its phase III clinical trial data on March 22 may have included outdated information that may have an effect on the reported efficacy. The board urged the company to review its efficacy data and "ensure the most accurate, up-to-date efficacy data be made public as quickly as possible."

In addition to the DSMB review, the AstraZeneca vaccine will only be considered for authorization after thorough review of the data by independent advisory committees of the U.S. Food and Drug Administration (FDA) and the U.S. Centers for Disease Control and Prevention (CDC).

AstraZeneca said that the data they released on March 22 were based on a prespecified interim analysis with a data cutoff of February 17. An internal review of the preliminary assessment of the primary analysis found that the results were consistent with the interim analysis. However, the company is completing additional validation of the statistical analysis to address the DSMB's concerns.

The company also stated that it is immediately engaging with the DSMB to share analysis with the most up-to-date efficacy data. They intend to make the results of the primary analysis public within 48 hours.

AstraZeneca closer to U.S. regulatory submission with interim results
AstraZeneca's COVID-19 vaccine candidate has demonstrated a vaccine efficacy rate of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing...
AstraZeneca COVID-19 vaccine deemed safe in U.K., EU
The benefits of AstraZeneca's COVID-19 vaccine far outweigh the risks, according to the U.K.'s Medicines and Healthcare products Regulatory Agency and...
AstraZeneca reaffirms that its COVID-19 vaccine is safe
AstraZeneca has reaffirmed that its COVID-19 vaccine is safe following concerns that the vaccine increases a person's risk of thrombotic events.

Copyright © 2021

Interphex 2021
October 19-21
New York City, New York United States
Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter